Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Novel Combination of Sorafenib and Celecoxib Provides Synergistic Anti-Proliferative and Pro-Apoptotic Effects in Human Liver Cancer Cells

12 Jun 2013

Abstract excerpt

Molecular targeted therapy has shown promise as a treatment for advanced hepatocellular carcinoma (HCC). Sorafenib, a multikinase inhibitor, recently received FDA approval for the treatment of advanced HCC. However, although sorafenib is well tolerated, concern for its safety has been expressed. Celecoxib (Celebrex®) is a selective cyclooxygenase-2 (COX-2) inhibitor which exhibits antitumor effects in human HCC...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Computational Drug Discovery Methods
Share to Inflammatory mediators and NSAID effects
Share to PI3K/AKT/mTOR signaling in cancer

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 23776502
DOI: 10.1371/journal.pone.0065569

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 5 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Novel Combination of Sorafenib and Celecoxib Provides Synergistic Anti-Proliferative and Pro-Apoptotic Effects in Human Liver Cancer CellsPMID 23776502Read ↗

COX-2-Dependent and COX-2-Independent Mode of Action of Celecoxib in Human Liver Cancer CellsSemantic proximity Read ↗

Molecular mechanisms of sorafenib action in liver cancer cellsSemantic proximity Read ↗

Synergistic inhibition of HCC and liver cancer stem cell proliferation by targeting RAS/RAF/MAPK and WNT/β-catenin pathways.Semantic proximity Read ↗

In vivo screen identifies LXR agonism potentiates sorafenib killing of hepatocellular carcinomaSemantic proximity Read ↗

Evaluation of the effect of biochanin b and Sorafenib on cell survival, growth, migration, colony formation and apoptosis in hepatocellular carcinomaSemantic proximity Read ↗

Combination therapy for hepatocellular carcinoma: additive preclinical efficacy of the HDAC inhibitor panobinostat with sorafenib.Semantic proximity Read ↗

mTOR Inhibitors Synergize on Regression, Reversal of Gene Expression, and Autophagy in Hepatocellular CarcinomaSemantic proximity Read ↗

Hypercholesterolemia-induced impairment in sorafenib functionality is overcome by avasimibe co-treatmentSemantic proximity Read ↗

Expression and Function Analysis of Mitotic Checkpoint Genes Identifies TTK as a Potential Therapeutic Target for Human Hepatocellular CarcinomaSemantic proximity Read ↗

Toripalimab combined with anlotinib as the second-line treatment for advanced hepatocellular carcinoma patients: a prospective, single arm phase II clinical studySemantic proximity Read ↗

Multitargeting and antimetastatic potentials of silibinin in human HepG-2 and PLC/PRF/5 hepatoma cells.Semantic proximity Read ↗

Deciphering molecular mechanisms of synergistic growth reduction in kinase inhibitor combinationsSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.